NCT04914234 Premedication With Atenolol Versus Metoprolol for Controlled Hypotensive Anesthesia During Nasal Surgeries
| NCT ID | NCT04914234 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Damanhour Teaching Hospital |
| Condition | Hypotension Drug-Induced |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2026-01-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 60 participants in total. It began in 2025-08-01 with a primary completion date of 2026-01-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Objectives: To compare the safety and efficacy of oral atenolol versus oral metoprolol as a premedication for controlled hypotensive anesthesia during nasal surgeries. Background: Mucosal bleeding is the most frequent complication with nasal surgeries, as it interferes with the optimal visualization of the intranasal anatomy, increases operation time, and consequently increases blood loss. There are several pharmacological and non-pharmacological techniques for the appropriate control of intraoperative bleeding. Patients and Methods: This was a prospective, randomized, double-blind, phase four, comparative clinical trial; carried out on 60 patients, who were candidates for nasal surgeries under general anesthesia at our hospital. Patients were randomly allocated into two equal groups; group A, received oral atenolol, and group M, received oral metoprolol.
Eligibility Criteria
Inclusion Criteria: * American Society of Anesthesiologists (ASA) physical status ≤ II * Age from 21 to 50 years Exclusion Criteria: * ASA physical status \> II * Age \< 21 years or \> 50 years * Pregnant women * Breastfeeding * Bronchial asthma * Chronic obstructive pulmonary disease * Diabetes Mellitus * Hypertension * Ischemic heart disease * Rheumatic heart disease * Heart failure * Heart block * Sick sinus syndrome * Sinus bradycardia * Chronic hypotension * Anemia (Hb \< 10 g/dl) * Renal or hepatic dysfunction * Central nervous system disease * Allergic fungal sinusitis * Patients on beta-blockers * Alcohol or drug abuse * Anticoagulation therapy, * Bleeding diathesis * Agents influencing autonomic nervous system * Allergy to the study drugs * Any contraindication of oral intake
Contact & Investigator
Ahmed M Shaat, MD
PRINCIPAL INVESTIGATOR
Damanhour Teaching Hospital
Frequently Asked Questions
Who can join the NCT04914234 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 50 Years, studying Hypotension Drug-Induced. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT04914234 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT04914234 currently recruiting?
Yes, NCT04914234 is actively recruiting participants. Contact the research team at ahmedshaat99@gmail.com for enrollment information.
Where is the NCT04914234 trial being conducted?
This trial is being conducted at Damanhūr, Egypt.
Who is sponsoring the NCT04914234 clinical trial?
NCT04914234 is sponsored by Damanhour Teaching Hospital. The principal investigator is Ahmed M Shaat, MD at Damanhour Teaching Hospital. The trial plans to enroll 60 participants.